Leerink Swan | GenomeWeb

Leerink Swan

To make up for the "lumpiness" of the market for genome-wide association studies, Affy will focus on applications that are downstream from GWAS, particularly in validation and routine testing, according to President and CEO Kevin King, who also shed some light on Affy's recent decision to sell its Clinical Services Laboratory to Navigenics.

NEJM last week published a quartet of perspectives offering a range of opinions on the value of GWAS and DTC testing, but two critical articles in particular caused financial analysts and the American news media to conclude that the perspectives could negatively impact companies that provide tools for these studies.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.